News
Search EMA's news announcements
Results (3786)
All ongoing clinical trials in the EU must be transitioned to the Clinical Trials Information System (CTIS) by 31 January 2025. This date marks the end of a three-year transition period that began when the Clinical Trials Regulation (CTR) became applicable in the EU.
News
Human
Clinical trials
Medicines
EMA has just launched the new Antimicrobial Sales and Use (ASU) Platform to support the collection of data by Member States on the sales and use of antimicrobials in animals.
News
Veterinary
Antimicrobial resistance
EMA will harness its unique experience in coordinating intra-regional medicines regulation to support the strengthening of the African regulatory network.
News
Corporate
On 24 January 2024, the CMDh endorsed precautionary measures recommended by EMA’s safety committee (PRAC) for the treatment of male patients with valproate medicines. These measures are to address a potential increased risk of neurodevelopmental disorders in children born to men treated with valproate during the 3 months before conception...
News
Human
Referrals
On 25 January 2024, EMA’s human medicines committee (CHMP) endorsed the measures recommended by the Pharmacovigilance Risk Assessment Committee (PRAC) to minimise the risks of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) for medicines containing pseudoephedrine.
News
EMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.
News
Human
Medicines
Referrals
EMA has published an overview of its key recommendations of 2023 regarding the authorisation and safety monitoring of veterinary medicines.
News
The European Medicines Agency (EMA) has released a major revision of its user guide for micro, small, and medium-sized enterprises (SMEs) in the pharmaceutical sector.
News
Human
Veterinary
Medicines
SME
News
Veterinary
Medicines
In 2023, EMA recommended 77 medicines for marketing authorisation. Of these, 39 had a new active substance which had never been authorised in the European Union (EU) before. Among these are a number of medicines that stand out due to their contribution to address public health needs or the innovation they represent.
News
Human
Medicines